查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1738565

全球感冒和流感藥物市場規模（按類型、應用、最終用戶、區域範圍和預測）

Global Cold And Flu Drugs Market Size By Type (Antihistamines, Decongestants), By Application (Prescription Medications, Over-the-Counter (OTC) Medications), By End User (Hospitals and Clinics, Retail Pharmacies), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

感冒和流感藥物市場規模和預測

2024 年感冒和流感藥物市場規模價值 168.5 億美元，預計到 2032 年將達到 293.9 億美元，2026 年至 2032 年的複合年成長率為 7.20%。

  • 感冒和流感藥物主要用於治療病毒性疾病（如感冒和流感）的症狀。這些藥物通常包括非處方 (OTC) 減充血劑、抗組織胺藥物、止咳藥和止痛藥，例如對乙醯胺酚和Ibuprofen。在某些情況下，複合抗病毒藥物可用於治療嚴重的流感症狀。雖然這些藥物無法治癒感染疾病，但它們確實可以緩解發燒、咳嗽、喉嚨痛和鼻塞等症狀，幫助患者緩解不適，並改善他們在患病期間的生活品質。
  • 隨著病毒性呼吸道疾病的流行和全球人口的成長，感冒和流感藥物的研發預計將蓬勃發展。藥物製劑的進步，例如用於治療多種疾病的聯合治療，預計將提高患者用藥的便利性和療效。
  • 新型抗病毒藥物和疫苗的研發，以及對抗流感病毒株的研發，將推動市場成長。隨著季節性流感預防和健康管理知識的不斷提高，尤其是在疫情期間，預計非處方和處方箋感冒和流感藥物的需求將保持在高位。遠端醫療和網路藥局的興起，將增加這些藥物的全球供應和消費量。

全球感冒和流感藥物市場動態

影響全球感冒和流感藥物市場的關鍵市場動態是：

關鍵市場促進因素

  • 流感和感冒發病率不斷上升：全球流感和感冒的高發性正在推動對感冒和流感藥物的需求。根據世界衛生組織 (WHO) 的數據，每年流感疫情在全球範圍內導致約 300 萬至 500 萬例重症患者。美國疾病管制與預防中心 (CDC) 估計，僅在美國，2010 年至 2020 年期間流感每年導致 900 萬至 4,100 萬人患病。
  • 人口老化加劇：老年人的免疫力較弱，更容易感染感冒和流感。根據聯合國經濟和社會事務部的數據，預計到2050年，全球65歲以上人口將達到15億，幾乎比2020年的7.27億翻倍。這一人口結構變化可能會增加對感冒和流感藥物的需求。
  • 醫療支出不斷成長：醫療支出不斷成長，尤其是在新興國家，正在推動感冒和流感藥物市場的成長。根據世界銀行的數據，全球醫療支出佔GDP的比例已從2000年的8.5%上升到2018年的9.8%。美國醫療保險和醫療補助服務中心(CMS)報告稱，到2020年，全國醫療支出將成長9.7%，達到4.1兆美元，佔GDP的19.7%。

主要問題

  • 抗病毒藥物抗藥性日益增強：流感病毒抗病毒藥物菌株的出現，對感冒和流感藥物市場構成了重大挑戰。隨著病毒變異，現有的抗病毒藥物，例如奧司他韋（達菲），可能不再對其產生反應。這種抗藥性會降低這些藥物的有效性，導致病程延長和感染率上升。製藥公司必須持續投入研發資金，以發現新的抗病毒藥物，既耗時又耗資。為了跟上病毒變異的步伐，需要不斷更新治療方法，這可能會對醫療資源造成壓力，並導致治療延遲。
  • 藥物核准的監管障礙：由於美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等機構的嚴格監管要求，獲得新型感冒和流感藥物的核准是一個漫長而複雜的過程。這些法規旨在確保藥物的安全性和有效性，但它們可能會減緩創新治療方法的推廣。臨床試驗必須證明該藥物不僅能緩解症狀，而且副作用極小。應對這些監管環境可能會增加成本和上市時間，並限制公司快速應對新出現的病毒株和不斷變化的患者需求的能力。
  • 副作用和安全隱患：許多感冒和流感藥物，尤其是非處方藥，都存在嗜睡、頭暈和過敏反應等副作用。有些成分，例如減充血劑和抗組織胺藥物，可能會對患有高血壓或心臟病等潛在疾病的患者造成併發症。這些安全隱患可能會導致消費者避免購買某些產品或尋求替代療法，進而影響市場需求。

主要趨勢

  • 呼吸道感染疾病盛行率上升：感冒和流感等呼吸道感染疾病盛行率上升是感冒和流感藥物市場的主要促進因素之一。氣候變遷、都市化進程加快以及人口老化使人們更容易受到病毒感染疾病。全球污染水平的上升正在削弱呼吸系統健康，使人們更容易受到感染疾病。這種持續的趨勢增加了對非處方藥和抗病毒藥物的需求，因為消費者尋求即時緩解症狀以保持生產力，尤其是在季節性流感流行和像COVID-19這樣的大流行病期間。
  • 非處方藥 (OTC) 的偏好日益成長：越來越多的消費者選擇自我治療，選擇非處方感冒和流感藥物。這一趨勢的促進因素包括藥品供應充足、價格實惠，以及希望在無需諮詢醫生的情況下緩解症狀。許多成藥提供組合療法，一種產品即可解決多種症狀。無需處方箋即可在藥局或線上平台購買這些藥物，其便利性是需求成長的主要因素。
  • 聯合治療需求：越來越多的消費者尋求聯合治療透過單一劑量治療多種症狀，例如鼻塞、咳嗽和頭痛。便利性是推動這一趨勢的因素，患者更傾向於選擇一體化解決方案，而不是針對不同症狀服用多種藥物。製藥公司為此開發了多種症狀療法，以緩解普通感冒和流感症狀。這些治療方法可以同時控制多種症狀，對生活忙碌的人群頗具吸引力，並成為感冒和流感藥物市場的主要驅動力。

目錄

第1章全球感冒與流感藥物市場介紹

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章 全球感冒流感藥物市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球感冒和流感藥物市場（按類型）

  • 概述
  • 抗組織胺藥
  • 減充血劑

6. 全球感冒和流感藥物市場（按應用）

  • 概述
  • 處方藥
  • 非處方藥

7. 感冒和流感藥物市場（按最終用戶分類）

  • 醫院診所
  • 零售藥局

8. 全球感冒和流感藥物市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

9. 全球感冒和流感藥物市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第10章 公司簡介

  • Johnson & Johnson
  • GlaxoSmithKline, Pfizer
  • Novartis
  • Sanofi
  • AstraZeneca
  • Bayer
  • Reckitt Benckiser
  • Procter & Gamble
  • Mylan
  • Pfizer

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 61559

Cold And Flu Drugs Market Size And Forecast

Cold And Flu Drugs Market size was valued at USD 16.85 Billion in 2024 and is projected to reach USD 29.39 Billion by 2032, growing at a CAGR of 7.20% from 2026 to 2032.

  • Cold and flu drugs are medical products that treat the symptoms of viral diseases, primarily the common cold and influenza. These medications often include over-the-counter (OTC) decongestants, antihistamines, cough suppressants, and pain relievers such as acetaminophen or ibuprofen. In some situations, prescription antiviral drugs are utilized to treat severe flu symptoms. While these treatments do not cure infections, they do alleviate symptoms such as fever, cough, sore throat, and nasal congestion, giving patients relief and enhancing their quality of life during the illness.
  • The market for cold and flu medications is expected to develop steadily as the prevalence of viral respiratory diseases rises and the worldwide population grows. Advances in medicine formulations, such as combination therapies that treat several ailments, are predicted to improve patient convenience and effectiveness.
  • The development of novel antiviral medicines and vaccinations to combat developing flu strains will aid market growth. With increased knowledge of seasonal flu prevention and health management, particularly during the pandemic, demand for both over-the-counter and prescription cold and flu treatments is expected to stay high. The advent of telemedicine and internet pharmacies will increase the global availability and consumption of these drugs.

Global Cold And Flu Drugs Market Dynamics

The key market dynamics that are shaping the global cold and flu drugs market include:

Key Market Drivers:

  • Increasing Incidence of Influenza and Common Cold: The high prevalence of influenza and common cold cases globally drives the demand for cold and flu medications. According to the World Health Organization (WHO), annual influenza epidemics result in about 3 to 5 million cases of severe illness worldwide. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in 9 million to 41 million illnesses annually between 2010 and 2020.
  • Growing Aging Population: The elderly population is more susceptible to cold and flu infections due to weakened immune systems. The United Nations Department of Economic and Social Affairs reports that the global population aged 65 and above is expected to reach 1.5 billion by 2050, nearly doubling from 727 million in 2020. This demographic shift is likely to increase the demand for cold and flu medications.
  • Rising Healthcare Expenditure: Increased healthcare spending, particularly in developing countries, is driving the growth of the cold and flu drugs market. The World Bank data shows that global health expenditure as a percentage of GDP has risen from 8.5% in 2000 to 9.8% in 2018. In the United States, the Centers for Medicare & Medicaid Services (CMS) reported that national health spending grew 9.7% to reach $4.1 trillion in 2020, accounting for 19.7% of GDP.

Key Challenges:

  • Growing Resistance to Antiviral Medications: The emergence of antiviral-resistant strains of flu viruses presents a significant challenge in the cold and flu drugs market. As viruses mutate, they can become less responsive to existing antiviral treatments, such as oseltamivir (Tamiflu). This resistance diminishes the effectiveness of these drugs, leading to prolonged illness and increased transmission rates. Pharmaceutical companies must continuously invest in research and development (R&D) to discover new antiviral agents, which can be time-consuming and costly. The need for updated treatments in response to viral mutations can strain healthcare resources and lead to treatment delays.
  • Regulatory Hurdles for Drug Approval: Gaining approval for new cold and flu drugs can be a lengthy and complex process due to stringent regulatory requirements from bodies like the FDA and EMA. These regulations aim to ensure the safety and efficacy of medications but can delay the introduction of innovative treatments. Clinical trials must demonstrate not only that the drugs alleviate symptoms but also that they have minimal side effects. Navigating this regulatory landscape can increase the cost and time to market, limiting the ability of companies to swiftly respond to emerging viral strains or changing patient needs.
  • Side Effects and Safety Concerns: Many cold and flu medications, especially OTC options, are associated with side effects like drowsiness, dizziness, or allergic reactions. Certain ingredients, such as decongestants or antihistamines, can cause complications in patients with pre-existing conditions like hypertension or heart disease. These safety concerns may lead consumers to avoid certain products or seek alternative treatments, thereby affecting market demand.

Key Trends:

  • Rising Prevalence of Respiratory Infections: The increasing incidence of respiratory infections, such as colds and the flu, is one of the primary drivers of the cold and flu drugs market. Changes in climate, growing urbanization, and an aging population contribute to higher susceptibility to viral infections. The global rise in pollution levels weakens respiratory health, making individuals more prone to infections. This ongoing trend increases the demand for over-the-counter medications and antiviral drugs, as consumers seek immediate relief from symptoms to maintain productivity, particularly during seasonal flu outbreaks and pandemics like COVID-19.
  • Growing Preference for Over-the-counter (OTC) Drugs: There is a growing shift toward self-medication, with consumers increasingly opting for OTC cold and flu drugs. This trend is driven by factors like easy accessibility, affordability, and the desire to manage symptoms without visiting healthcare professionals. Many OTC medications offer combination treatments, addressing multiple symptoms in a single product. The convenience of purchasing these drugs at pharmacies or online platforms without a prescription has contributed significantly to their rising demand
  • Demand for Combination Therapies: Consumers are increasingly seeking combination therapies that address multiple symptoms such as congestion, cough, and headaches in a single dose. This trend is driven by the convenience factor, as patients prefer all-in-one solutions rather than taking multiple drugs for different symptoms. Pharmaceutical companies have responded by developing multi-symptom medications that offer relief for common cold and flu symptoms. The efficiency of these treatments in managing several symptoms simultaneously appeals to individuals with busy lifestyles, making them a significant driver of the cold and flu drugs market.

Global Cold And Flu Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global cold and flu drugs market:

North America:

  • North America's dominance in the cold and flu drugs market, including the high incidence of respiratory illnesses and an advanced healthcare infrastructure. The United States alone experiences millions of flu cases annually, with the CDC reporting an average of 9 million to 45 million influenza cases each year. This, combined with widespread access to healthcare and over-the-counter (OTC) medications, creates a robust demand for cold and flu treatments.
  • The aging population in North America, which is more vulnerable to respiratory infections, fuels the need for effective and accessible cold and flu drugs. Increased awareness around self-medication for minor ailments and the availability of OTC products further support the market's growth.
  • The cold and flu drugs market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2028. Heightened awareness due to the COVID-19 pandemic has led to a surge in demand for respiratory illness treatments, further boosting the market. Significant investments in research and development, like the NIH's allocation of $484 million for influenza research in 2023, underline the region's commitment to advancing respiratory treatments.

Asia Pacific:

  • The cold and flu drugs market in the Asia Pacific region is experiencing rapid growth. The region's large and expanding population, which accounts for about 60% of the global population, plays a central role in the market's expansion. Rising urbanization and increased pollution levels contribute to a higher incidence of respiratory illnesses, fueling the demand for cold and flu medications. The growing middle class and rising disposable incomes across the region enable more people to invest in healthcare products, including over-the-counter (OTC) medications. Southeast Asia, in particular, has seen annual healthcare expenditure growth rates between 6-12%, highlighting a significant increase in healthcare access and spending.
  • Another critical driver is the region's aging population, particularly in East Asia and the Pacific, where the percentage of people aged 60 and above is expected to rise from 13.8% in 2020 to 27.6% by 2050. Older adults are more vulnerable to respiratory infections, increasing the demand for cold and flu drugs. The region's expanding healthcare infrastructure, government initiatives to improve healthcare access, and the rise of e-commerce platforms have made cold and flu medications more accessible.

Global Cold And Flu Drugs Market: Segmentation Analysis

The Global Cold And Flu Drugs Market is Segmented on the basis of Type, Application, End User, And Geography.

Cold And Flu Drugs Market, By Type

  • Antihistamines
  • Decongestants

Based on Type, the market is fragmented into Antihistamines and decongestants. Antihistamines dominate due to their widespread use in managing symptoms such as sneezing, runny nose, and watery eyes, which are common in colds and flu. They are a key component in many over-the-counter cold remedies and are favored for their ability to provide quick relief from allergy-like symptoms associated with viral infections. Decongestants are a rapidly growing segment, driven by the rising demand for medications that relieve nasal congestion and sinus pressure, particularly during flu seasons. Decongestants are often sought after for their effectiveness in reducing inflammation and easing breathing, making them essential in cold and flu treatment.

Cold And Flu Drugs Market, By Application

  • Prescription Medications
  • Over-the-Counter (OTC) Medications

Based on Application, the market is divided into Prescription Medications and over-the-counter (OTC) Medications. Over-the-counter (OTC) Medications dominate due to their ease of accessibility and wide availability without the need for a doctor's prescription. Consumers prefer OTC medications for immediate relief from common cold and flu symptoms, making them the go-to choice during seasonal outbreaks. This segment is driven by consumer awareness and the convenience of purchasing from pharmacies, supermarkets, and online platforms. Prescription Medications are rapidly growing, particularly for severe or persistent cases that require more specialized treatments.

Cold And Flu Drugs Market, By End User

  • Hospitals and Clinics
  • Retail Pharmacies

Based on End User, the market is segmented into Hospitals and Clinics, and Retail Pharmacies. Retail Pharmacies dominate due to their accessibility and convenience for consumers seeking over-the-counter medications. Retail pharmacies are widely available, making them the first point of contact for people looking for quick relief from cold and flu symptoms. The rise of online pharmacies has further fueled this segment's growth. Hospitals and Clinics represent a rapidly growing segment, particularly for more severe cases requiring prescription medications or treatment for complications. Increased healthcare visits during flu seasons and the growing preference for professional consultations in complex cases are driving the demand in this segment.

Cold And Flu Drugs Market, By Geography

  • North America
  • Asia Pacific
  • Europe
  • Rest of the world
  • On the basis of geographical analysis, the Global Cold And Flu Drugs Market is classified into North America, Asia Pacific, Europe, and Rest of the world. North America stands out as a dominant region due to its advanced healthcare system, high awareness of cold and flu treatments, and strong consumer demand for over-the-counter drugs. Asia Pacific is experiencing rapid growth, driven by increasing healthcare access, rising disposable incomes, and a growing population.

Key Players

The "Global Cold And Flu Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, Sanofi, AstraZeneca, Bayer, Reckitt Benckiser, Procter & Gamble, and Mylan. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Cold And Flu Drugs Market Recent Developments
  • In September 2023, BMS disclosed that as part of a strategic license and partnership to create and market obexelimab, a brand-new, bi-functional antibody for autoimmune disorders, it will pay Zenas BioPharma $50 million upfront.
  • In May 2022, Nature's Way Products, LLC, announced a significant expansion of its Green Bay, Wisconsin, Gummy factory. Incorporating production, packaging, and warehouse space, the development will increase the present 80,000 square feet by 116,000 square feet. Early summer was the planned start date, and the project should be finished by the end of the third quarter of 2023.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL COLD AND FLU DRUGS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL COLD AND FLU DRUGS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL COLD AND FLU DRUGS MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Antihistamines
  • 5.3 Decongestants

6 GLOBAL COLD AND FLU DRUGS MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Prescription Medications
  • 6.3 Over-the-Counter (OTC) Medications

7 COLD AND FLU DRUGS MARKET, BY END USER

  • 7.1 Hospitals and Clinics
  • 7.2 Retail Pharmacies

8 GLOBAL COLD AND FLU DRUGS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 The U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 The U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 7.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL COLD AND FLU DRUGS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Johnson & Johnson
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 GlaxoSmithKline, Pfizer
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Novartis
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Sanofi
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 AstraZeneca
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bayer
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Development
  • 10.7 Reckitt Benckiser
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Procter & Gamble
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Development
  • 10.9 Mylan
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Development
  • 10.10 Pfizer
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Development

11 Appendix

  • 11.1 Related Research